Date | Title | |
December 14, 2017 | BeyondSpring Meets Primary Objective in Phase 2 Portion of Phase 2/3 Trial (Study 105) with Plinabulin for the Prevention of Docetaxel Chemotherapy-Induced Neutropenia (CIN) |  |
December 7, 2017 | BeyondSpring to Webcast Key Opinion Leader Event in NYC on Dec. 14, 2017 |  |
December 4, 2017 | BeyondSpring’s Lead Asset, Plinabulin, Recognized as 2017 National Science and Technology Major Project in China |  |
November 30, 2017 | BeyondSpring Initiates Global Phase 2/3 Trial with Plinabulin in China for the Prevention of Chemotherapy-Induced Neutropenia to Demonstrate Superiority |  |
November 9, 2017 | BeyondSpring Reports Third Quarter 2017 Operational and Financial Results |  |
November 2, 2017 | BeyondSpring to Host Quarterly Operational Update Conference Call on November 9, 2017 |  |
October 26, 2017 | BeyondSpring Announces the First Patient Enrolled in China in its Global Phase 2/3 Trial with Plinabulin for the Prevention of Chemotherapy-Induced Neutropenia |  |
October 23, 2017 | BeyondSpring Receives Two Grants in China to Further Develop Innovative Drug Pipeline |  |
October 18, 2017 | BeyondSpring Chief Medical Officer to Present at the 2017 BIO Investor Forum on Oct. 18 in San Francisco |  |
September 5, 2017 | BeyondSpring to Present at the 19th Annual Rodman & Renshaw Global Investment Conference |  |
August 21, 2017 | BeyondSpring Provides Operational Update for Second Quarter of 2017 |  |
August 17, 2017 | BeyondSpring to Present at the 2017 Southern California Investor Conference |  |
August 14, 2017 | BeyondSpring to Host Quarterly Operational Update Conference Call on August 21, 2017 |  |
July 6, 2017 | China FDA Approves CTAs for BeyondSpring’s Second Global Plinabulin Registrational Trial for Chemotherapy-Induced Neutropenia Prevention |  |
June 15, 2017 | BeyondSpring Chief Medical Officer to Present Clinical Data for Lead Asset Plinabulin at 2017 BIO International Convention in San Diego |  |
June 2, 2017 | BeyondSpring to Present at the Jefferies 2017 Healthcare Conference |  |
June 1, 2017 | BeyondSpring to Attend Jefferies 2017 Healthcare Conference |  |
May 22, 2017 | BeyondSpring Reports First Quarter 2017 Financial Results |  |
May 8, 2017 | BeyondSpring Chief Medical Officer to Present at Three Prominent Industry Conferences in May 2017 |  |
May 1, 2017 | BeyondSpring Files Its 2016 Annual Report on Form 20-F |  |
April 28, 2017 | BeyondSpring Provides Quarterly Operational Update and Full Year 2016 Results |  |
April 26, 2017 | BeyondSpring to Participate in Joseph Gunnar’s Pioneers 2017 Conference on May 2 in New York |  |
April 25, 2017 | BeyondSpring Enrolls First U.S. Patient in Phase 2/3 Clinical Trial of Plinabulin for Neutropenia Prevention |  |
April 13, 2017 | BeyondSpring to Host Quarterly Operational Update Conference Call on April 28, 2017 |  |
March 22, 2017 | BeyondSpring Chief Medical Officer to Present on Lead Asset Plinabulin for Chemotherapy-Induced Neutropenia Prevention at BIO-Europe Spring 2017 |  |
March 20, 2017 | BeyondSpring Lead Asset Plinabulin's Anti-Cancer Mechanism Accepted for Poster Presentation at the 2017 Keystone Symposia in British Columbia |  |
March 14, 2017 | BeyondSpring Chief Medical Officer to Present Clinical Data for Lead Asset Plinabulin for Non-Small Cell Lung Cancer Treatment and Neutropenia Prevention at 2017 BIO Asia International Conference in Tokyo |  |
March 9, 2017 | Nasdaq Welcomes BeyondSpring Inc. (Nasdaq: BYSI) to The Nasdaq Stock Market |  |
March 9, 2017 | BeyondSpring Inc. Prices Initial Public Offering and Concurrent Private Placement of $54.31 M |  |
February 21, 2017 | BeyondSpring’s Promising Clinical Data for Lead Asset on Non-Small Cell Lung Cancer Treatment Selected for Presentation at 2017 ASCO-SITC Clinical Immuno-Oncology Symposium |  |
January 24, 2017 | FDA Accepts BeyondSpring IND Application for Plinabulin for the Prevention of Chemotherapy-Induced Neutropenia |  |
January 10, 2017 | BeyondSpring Inc. to Present at Biotech Showcase 2017 During Annual JPMorgan Healthcare Conference on January 10 in San Francisco |  |